Hepatic Events Prevention by Antihyperglycemic Therapies and Intervention Comparisons in Type 2 Diabetes: The HEPATIC-T2DM Network Meta-analysis - PubMed
3 hours ago
- #network meta-analysis
- #liver outcomes
- #type 2 diabetes
- Type 2 diabetes increases liver disease risk, but hepatic effects of antidiabetic drugs are not well understood.
- A network meta-analysis of 46 observational studies compared drug classes on major adverse liver outcomes.
- Thiazolidinediones showed the lowest association with hepatocellular carcinoma incidence among the drugs studied.
- GLP-1RAs were linked to the lowest risk for decompensation, variceal bleeding, and hepatic encephalopathy.
- SGLT2 inhibitors were least associated with cirrhosis and liver-related mortality.
- Findings are from observational studies, so causal conclusions cannot be drawn, and randomized trials are needed.